Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BRACE trial

- PMLiVE

Stick or Twist? Healthcare brands in a (post) COVID-19 world

How have our perceptions of healthcare brands and our purchasing habits changed during the COVID-19 pandemic?

Say Communications

- PMLiVE

US pauses shipments of Eli Lilly’s COVID-19 antibody treatment due to variant concerns

Laboratory analyses found the therapy was not effective against variants first discovered in South Africa and Brazil

- PMLiVE

Oxford University to study antiparasitic drug ivermectin in COVID-19 trial

The potential COVID-19 treatment will be investigated as part of the large-scale PRINCIPLE trial

- PMLiVE

GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients

Final efficacy analysis confirms previous positive findings from interim analysis

- PMLiVE

Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome

TNX-102 is already in phase 3 development for the treatment of fibromyalgia

- PMLiVE

Gilead reveals real-world data for COVID-19 drug Veklury

Veklury significantly lowered the risk of mortality compared with matched controls in real-world analysis, says Gilead

- PMLiVE

Court rules on AZ and EU’s COVID-19 vaccine dispute

The Court in Brussels has ordered AZ to deliver a total of 80.2 million doses to the EU by 27 September 2021

- PMLiVE

US announces $3bn funding boost for antiviral COVID-19 treatments

Funding will go towards the discovery, development and manufacturing of antiviral medicines

- PMLiVE

Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy

Vaccine candidate failed to meet prespecified measure of statistical success in clinical trial

- PMLiVE

Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses

Pfizer/BioNTech and AZ vaccines found to be 96% and 92% effective against variant, respectively

- PMLiVE

Regeneron’s COVID-19 drug boosts survival in hospitalised patients lacking antibodies

REGEN-COV reduced the risk of death among patients who did not have a natural antibody response

- PMLiVE

US trial data shows Novavax’s COVID-19 vaccine is 90% effective

The jab was also found to provide protection against variants of concern and variants of interest

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links